February 13th 2025
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.
American Thoracic Society Calls for Equitable Access on World Lung Day